TY - JOUR
T1 - Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease
AU - Harms, Ashley S.
AU - Thome, Aaron D.
AU - Yan, Zhaoqi
AU - Schonhoff, Aubrey M.
AU - Williams, Gregory P.
AU - Li, Xinru
AU - Liu, Yudong
AU - Qin, Hongwei
AU - Benveniste, Etty N.
AU - Standaert, David G.
N1 - Funding Information:
The work from these studies is generously supported by the RJG Foundation , NIH 2P30 NS047466 , and NIH/NINDS P20 NS092530 .
Publisher Copyright:
© 2017
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Accumulation of alpha-synuclein (α-syn) in the central nervous system (CNS) is a core feature of Parkinson disease (PD) that leads to activation of the innate immune system, production of inflammatory cytokines and chemokines, and subsequent neurodegeneration. Here, we used heterozygous reporter knock-in mice in which the first exons of the fractalkine receptor (CX3CR1) and of the C-C chemokine receptor type 2 (CCR2) are replaced with fluorescent reporters to study the role of resident microglia (CX3CR1 +) and infiltrating peripheral monocytes (CCR2 +), respectively, in the CNS. We used an α-syn mouse model induced by viral over-expression of α-syn. We find that in vivo, expression of full-length human α-syn induces robust infiltration of pro-inflammatory CCR2 + peripheral monocytes into the substantia nigra. Genetic deletion of CCR2 prevents α-syn induced monocyte entry, attenuates MHCII expression and blocks the subsequent degeneration of dopaminergic neurons. These results demonstrate that extravasation of pro-inflammatory peripheral monocytes into the CNS plays a key role in neurodegeneration in this model of PD synucleinopathy, and suggest that peripheral monocytes may be a target of neuroprotective therapies for human PD.
AB - Accumulation of alpha-synuclein (α-syn) in the central nervous system (CNS) is a core feature of Parkinson disease (PD) that leads to activation of the innate immune system, production of inflammatory cytokines and chemokines, and subsequent neurodegeneration. Here, we used heterozygous reporter knock-in mice in which the first exons of the fractalkine receptor (CX3CR1) and of the C-C chemokine receptor type 2 (CCR2) are replaced with fluorescent reporters to study the role of resident microglia (CX3CR1 +) and infiltrating peripheral monocytes (CCR2 +), respectively, in the CNS. We used an α-syn mouse model induced by viral over-expression of α-syn. We find that in vivo, expression of full-length human α-syn induces robust infiltration of pro-inflammatory CCR2 + peripheral monocytes into the substantia nigra. Genetic deletion of CCR2 prevents α-syn induced monocyte entry, attenuates MHCII expression and blocks the subsequent degeneration of dopaminergic neurons. These results demonstrate that extravasation of pro-inflammatory peripheral monocytes into the CNS plays a key role in neurodegeneration in this model of PD synucleinopathy, and suggest that peripheral monocytes may be a target of neuroprotective therapies for human PD.
KW - C-C chemokine receptor type 2 (CCR2)
KW - Fractalkine receptor (CX3CR1) Major histocompatibility complex II (MHCII)
KW - Microglia
KW - Monocytes
KW - Parkinson disease (PD)
KW - α-syn (alpha-synuclein)
UR - http://www.scopus.com/inward/record.url?scp=85034624068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034624068&partnerID=8YFLogxK
U2 - 10.1016/j.expneurol.2017.11.010
DO - 10.1016/j.expneurol.2017.11.010
M3 - Article
C2 - 29155051
AN - SCOPUS:85034624068
VL - 300
SP - 179
EP - 187
JO - Experimental Neurology
JF - Experimental Neurology
SN - 0014-4886
ER -